Onconova Therapeutics (ONTX) vs. Strongbridge Biopharma (SBBP) Financial Review

Onconova Therapeutics (NASDAQ: ONTX) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Insider and Institutional Ownership

25.4% of Onconova Therapeutics shares are held by institutional investors. Comparatively, 57.5% of Strongbridge Biopharma shares are held by institutional investors. 27.3% of Onconova Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Onconova Therapeutics and Strongbridge Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Onconova Therapeutics -2,855.94% -558.97% -144.30%
Strongbridge Biopharma N/A -181.90% -38.62%

Earnings and Valuation

This table compares Onconova Therapeutics and Strongbridge Biopharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Onconova Therapeutics $5.55 million 3.07 -$19.66 million ($3.03) -0.52
Strongbridge Biopharma N/A N/A -$48.59 million ($3.38) -2.01

Onconova Therapeutics has higher revenue and earnings than Strongbridge Biopharma. Strongbridge Biopharma is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Onconova Therapeutics and Strongbridge Biopharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconova Therapeutics 0 0 4 0 3.00
Strongbridge Biopharma 0 0 4 0 3.00

Onconova Therapeutics currently has a consensus price target of $7.33, indicating a potential upside of 364.14%. Strongbridge Biopharma has a consensus price target of $13.50, indicating a potential upside of 98.53%. Given Onconova Therapeutics’ higher possible upside, equities research analysts plainly believe Onconova Therapeutics is more favorable than Strongbridge Biopharma.

Summary

Onconova Therapeutics beats Strongbridge Biopharma on 6 of the 10 factors compared between the two stocks.

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit